Log In
Print
BCIQ
Print
Print this Print this
 

Synriam, arterolane maleate/piperaquine phosphate

  Manage Alerts
Collapse Summary General Information
Company Ranbaxy Laboratories Ltd.
Description150 mg arterolane maleate and 750 mg piperaquine phospate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationMalaria
Indication DetailsTreat malaria caused by Plasmodium Vivax; Treat malaria in adults
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today